GoodRx Holdings, Inc.

NasdaqGS:GDRX Stock Report

Market Cap: US$1.6b

GoodRx Holdings Valuation

Is GDRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GDRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GDRX ($4.31) is trading below our estimate of fair value ($15.47)

Significantly Below Fair Value: GDRX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GDRX?

Key metric: As GDRX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GDRX. This is calculated by dividing GDRX's market cap by their current revenue.
What is GDRX's PS Ratio?
PS Ratio2.1x
SalesUS$790.39m
Market CapUS$1.63b

Price to Sales Ratio vs Peers

How does GDRX's PS Ratio compare to its peers?

The above table shows the PS ratio for GDRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.6x
CERT Certara
4.1x9.6%US$1.6b
NXGN NextGen Healthcare
2.3x6.7%US$1.6b
TDOC Teladoc Health
0.6x0.7%US$1.5b
SDGR Schrödinger
7.2x18.9%US$1.4b
GDRX GoodRx Holdings
2.1x6.3%US$1.6b

Price-To-Sales vs Peers: GDRX is good value based on its Price-To-Sales Ratio (2.1x) compared to the peer average (4x).

Price to Sales Ratio vs Industry

How does GDRX's PS Ratio compare vs other companies in the US Healthcare Services Industry?

14 CompaniesPrice / SalesEstimated GrowthMarket Cap
AMWL American Well
0.5x10.9%US$119.33m
MPLN MultiPlan
0.1x1.7%US$84.25m
CCLD CareCloud
0.4x1.7%US$45.47m
HCTI Healthcare Triangle
0.4xn/aUS$6.40m
GDRX 2.1xIndustry Avg. 2.0xNo. of Companies14PS0246810+
14 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: GDRX is expensive based on its Price-To-Sales Ratio (2.1x) compared to the US Healthcare Services industry average (2x).

Price to Sales Ratio vs Fair Ratio

What is GDRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GDRX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.1x
Fair PS Ratio5.2x

Price-To-Sales vs Fair Ratio: GDRX is good value based on its Price-To-Sales Ratio (2.1x) compared to the estimated Fair Price-To-Sales Ratio (5.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GDRX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.31
US$7.28
+68.9%
22.1%US$10.00US$4.50n/a16
Nov ’25US$6.19
US$9.47
+53.0%
23.3%US$16.00US$5.00n/a17
Oct ’25US$6.93
US$9.56
+37.9%
22.7%US$16.00US$5.00n/a18
Sep ’25US$7.90
US$9.56
+21.0%
22.7%US$16.00US$5.00n/a18
Aug ’25US$8.75
US$9.60
+9.7%
22.4%US$16.00US$5.00n/a18
Jul ’25US$7.82
US$9.51
+21.7%
22.3%US$16.00US$5.00n/a19
Jun ’25US$7.87
US$9.33
+18.5%
23.3%US$16.00US$5.00n/a19
May ’25US$6.97
US$8.68
+24.5%
22.5%US$14.00US$5.00n/a19
Apr ’25US$7.10
US$8.66
+22.0%
23.2%US$14.00US$5.00n/a18
Mar ’25US$8.35
US$8.44
+1.1%
24.6%US$14.00US$5.00n/a17
Feb ’25US$6.13
US$7.09
+15.7%
24.6%US$12.00US$4.50n/a16
Jan ’25US$6.70
US$6.90
+3.0%
26.5%US$12.00US$5.00n/a15
Dec ’24US$6.37
US$6.72
+5.5%
26.7%US$12.00US$5.00n/a16
Nov ’24US$5.04
US$8.67
+72.0%
17.6%US$12.00US$7.00US$6.1915
Oct ’24US$5.63
US$8.63
+53.2%
17.2%US$12.00US$7.00US$6.9316
Sep ’24US$6.55
US$8.39
+28.1%
19.0%US$12.00US$6.00US$7.9018
Aug ’24US$8.67
US$6.79
-21.7%
23.1%US$12.00US$5.00US$8.7518
Jul ’24US$5.52
US$6.41
+16.1%
14.2%US$8.00US$5.00US$7.8219
Jun ’24US$5.37
US$6.41
+19.3%
14.2%US$8.00US$5.00US$7.8719
May ’24US$4.58
US$6.95
+51.7%
13.8%US$9.00US$6.00US$6.9719
Apr ’24US$6.25
US$6.95
+11.2%
13.8%US$9.00US$6.00US$7.1019
Mar ’24US$5.50
US$6.92
+25.8%
14.5%US$9.00US$6.00US$8.3519
Feb ’24US$5.91
US$6.97
+18.0%
20.5%US$10.00US$4.50US$6.1319
Jan ’24US$4.66
US$7.13
+53.0%
23.5%US$11.00US$4.50US$6.7019
Dec ’23US$5.16
US$7.13
+38.2%
23.5%US$11.00US$4.50US$6.3719
Nov ’23US$5.32
US$9.53
+79.1%
18.7%US$13.00US$6.00US$5.0418

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Centene

US$29.2b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$59.10

7D

1.8%

1Y

-20.4%

Elevance Health

US$91.4b

Operates as a health benefits company in the United States.

ELV

US$397.48

7D

-3.3%

1Y

-17.2%

CVS Health

US$70.2b

Provides health solutions in the United States.

CVS

US$56.83

7D

4.7%

1Y

-17.8%